Indo Us Bio-Tech Share Price Today

Indo US Bio-Tech passes all five AGM resolutions including auditor appointment

Indo US Bio-Tech Limited passed all five resolutions at its 22nd AGM held on September 30, 2026. Resolutions included adoption of FY26 financials, auditor appointment, and borrowing limit approval. Total votes polled were 1,48,41,548, with 98.52% in favour across all items. Promoter group held 1,36,93,643 shares, while public non-institutions voted 11,47,905 shares. No institutional shareholder votes were recorded during the remote e-voting process.

Indo US Bio-Tech sets Sept 30 AGM; seeks ₹250 cr borrowing limit

Indo US Bio-Tech holds 22nd AGM on Sept 30, 2026, via VC/OAVM. Bhagat & Associates proposed as statutory auditors for five years. Board seeks approval for borrowing up to ₹250 crore above capital/reserves. Reappointment of director Priyanka Samarth Patel on agenda. Related-party transaction limit set at ₹10 crore per type.

Indo US Bio-Tech net profit falls 35% in Q1FY27 to ₹3.04 crore

Indo US Bio-Tech's Q1FY27 results show a 35% drop in net profit to ₹3.04 crore despite a 7% rise in revenue to ₹32.99 crore. The profit contraction was driven by the normalization of employee benefit expenses following a large reversal in the prior year. Production costs remained stable, indicating consistent operational efficiency in its seed cultivation business.

Indo US Bio-Tech Q1 Results: Net profit drops 35% YoY to ₹3 crore

Indo US Bio-Tech reported Q1FY26 net profit of ₹3.04 crore, down 35% YoY, amid rising production and finance costs. Revenue grew 7% to ₹33 crore. Statutory auditors gave clean review report.

Indo Us Bio-Tech shareholders approve director regularization and auditor appointment

Indo Us Bio-Tech Limited shareholders have overwhelmingly approved the regularization of Hemanshi Darsh Soni as a non-executive independent director and the appointment of M/s. Bhagat & Associates as statutory auditor through a remote e-voting postal ballot. Conducted between July 5 and August 3, 2026, the voting process saw 100% support for both resolutions, with promoters casting all votes in favor and public non-institutional shareholders showing a 99.9983% approval rate. The appointments strengthen the company's board independence and ensure continuity in financial reporting integrity.

Indo US Bio-Tech appoints Bhagat & Associates as statutory auditor

Indo US Bio-Tech Limited appointed M/s. Bhagat & Associates as statutory auditor effective June 15, 2026, following the resignation of M/s. Gautam N Associates. The resignation was due to administrative and operational restructuring of audit assignments. The new auditor's term runs until the conclusion of the next General Meeting, subject to shareholder approval.